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ALN

:   axillary‐lymph node

CECT

:   contrast‐enhanced computed tomography

CER

:   chemotherapy‐effective rate

CF

:   cisplatin plus 5‐fluorouracil

DCF

:   docetaxel, cisplatin, plus 5‐fluorouracil

ESCC

:   esophageal squamous cell carcinoma

HCER

:   high CER

LCER

:   low CER

LN

:   lymph node

LNM

:   lymph node metastasis

nCRT

:   neoadjuvant chemoradiotherapy

nCT

:   neoadjuvant chemotherapy

non‐MLN

:   non‐metastatic LN

OS

:   overall survival

pp‐MLN

:   plausible positive metastatic LN

RFS

:   recurrence‐free survival

TRG‐LN

:   TRG of the lymph node

TRG‐PT

:   TRG of the primary tumor

TRG

:   tumor regression grade

1. INTRODUCTION {#cas13596-sec-0001}
===============

Neoadjuvant chemoradiotherapy followed by surgery has been one of the standard treatments for locally advanced thoracic ESCC, and nCT followed by surgery is the standard in Japan, based on the results of many clinical trials.[1](#cas13596-bib-0001){ref-type="ref"}, [2](#cas13596-bib-0002){ref-type="ref"}, [3](#cas13596-bib-0003){ref-type="ref"} These studies have shown that nCT or nCRT improves the prognosis of patients with ESCC. We have reported that higher TRG‐PT is a positive prognostic factor, whereas residual LNM is a negative prognostic factor.[4](#cas13596-bib-0004){ref-type="ref"}

Neoadjuvant chemotherapy followed by surgery has been the standard therapy for breast cancer patients, with the aim of preserving breast organ.[5](#cas13596-bib-0005){ref-type="ref"} Therefore, lymph node tissue modified by nCT undergoes pathological examination. Not only TRG‐PT but also TRG‐LN involved in the metastatic tumor has been routinely subjected to pathological examination, because TRG of primary and metastatic tumors has been implicated in predicting prognosis.[6](#cas13596-bib-0006){ref-type="ref"}, [7](#cas13596-bib-0007){ref-type="ref"}, [8](#cas13596-bib-0008){ref-type="ref"} No residual tumor in ALN after nCT is well known to be a better prognostic factor, even in breast cancer patients who still have residual tumor at the primary site.[7](#cas13596-bib-0007){ref-type="ref"}

In contrast, regarding patients with ESCC who underwent nCRT or nCT using an anti‐cancer effective regimen, residual LNM remains one of the poor prognostic factors. It suggests that it may be necessary for pathologists to determine the TRG of both primary and metastatic tumors involving LN in ESCC patients as well as in breast cancer patients who underwent nCT. It remains unknown whether TRG‐PT or TRG‐LN is associated with prognosis in ESCC patients. The aim of the present study was to clarify the significance of TRG‐LN as a prognostic factor in ESCC patients who had undergone nCT followed by surgery.

2. PATIENTS AND METHODS {#cas13596-sec-0002}
=======================

2.1. Patients {#cas13596-sec-0003}
-------------

Patients with locally advanced esophageal cancer who had undergone a combination therapy of nCT followed by surgery at the National Cancer Center Hospital East between January 2008 and March 2013 were enrolled. Eligibility criteria were as follows: (i) patients pathologically diagnosed using biopsy specimens, with squamous cell carcinoma prior to receiving any nCT; (ii) patients who underwent total or subtotal thoracic esophagectomy with regional lymph node dissection after nCT; (iii) patients whose performance status according to ECOG was 0‐1; and (iv) patients whose dissected LN included at least 1 pp‐MLN where viable and/or degenerated ESCC cells and/or tissue modifications. Patients who received macroscopically incomplete resection after nCT or died in hospital post‐surgery were excluded from this study. However, patients who were not able to receive a scheduled complete course of nCT were included. Consequently, 110 ESCC patients were enrolled in the study. Clinical staging before nCT was determined according to UICC‐TNM classification (7th edition),[9](#cas13596-bib-0009){ref-type="ref"} based on endoscopic findings and CECT. This study protocol was approved by the institutional review board of the National Cancer Center (2014‐357).

2.2. Neoadjuvant chemotherapy {#cas13596-sec-0004}
-----------------------------

The regimen of nCT was either 2 courses of CF,[3](#cas13596-bib-0003){ref-type="ref"} or 3 courses of DCF. Each course was given every 3 weeks. All patients were scheduled to receive endoscopic examination and CECT after each course of the above chemotherapy for evaluating the therapeutic effect. The patients underwent surgery after interrupting the course of nCT. Patients who did not respond to nCT or who presented with severe toxicity attributable to the nCT were included in this study.

2.3. Histopathological examinations {#cas13596-sec-0005}
-----------------------------------

Pathological diagnosis of surgically resected specimens was routinely carried out according to the Japanese Classification of Esophageal Cancer.[10](#cas13596-bib-0010){ref-type="ref"} Microscopically incomplete resection was recorded as incomplete resection (R1), and complete resection was recorded as R0. TRG‐PT was classified into 5 categories (grade 0, no therapeutic effect; grade 1a, viable cancer cells ≥2/3; grade 1b, 1/3 ≤ viable cancer cells \<2/3; grade 2, viable cancer cells \<1/3; and grade 3, no viable cancer cells) according to the ratio of viable cancer cells per tumor tissue.[4](#cas13596-bib-0004){ref-type="ref"}

2.4. TRG of metastatic lymph nodes {#cas13596-sec-0006}
----------------------------------

We newly determined TRG‐LN in the present study as following 5 steps (Figure [S1](#cas13596-sup-0001){ref-type="supplementary-material"}).

Each dissected LN was classified into 2 categories, including non‐MLN and pp‐MLN. The definition of both categories is as follows: non‐MLN in which any viable ESCC cells, degenerated ESCC cells, or tissue modifications including necrosis and granulomatous reactions were not observed at all; and pp‐MLN in which viable and/or degenerated ESCC cells and/or tissue modifications were observed in contrast to non‐MLN.TRG‐LN grade (grades 0, 1a, 1b, 2, or 3) in the individual pp‐MLN were pathologically determined according to the same criteria as that of the TRG‐PT (Figure [1](#cas13596-fig-0001){ref-type="fig"}).In each patient, the number of all pp‐MLN and pp‐MLN with grades 1a, 1b, 2, and 3 were counted.The ratio of the number of pp‐MLN that were categorized as grades 1a, 1b, 2, and 3 regarding TRG‐LN to all pp‐MLN (categorized as grades 0, 1a, 1b, 2, and 3 regarding TRG‐LN) was calculated. We defined the ratio as the CER.We classified CER into two categories: LCER (low rate, ≥0% and \<50%) or HCER (high rate, ≥50% and ≤100%). We determined total TRG‐LN evaluation for each patient based on the definition of CER (LCER or HCER), as described above. In addition, we determined the highest or the lowest TRG‐LN grades of pp‐MLN in each patient, and examined relationships between RFS, and the highest TRG‐LN grade or the lowest TRG‐LN grade.

![Tumor regression grade of metastatic ESCC cells involving lymph nodes. A, Grade 0 tumor regression grade of lymph node (TRG‐LN). Residual ESCC cells are observed (enclosed by the solid line), and no degenerated ESCC cells are seen. B, Grade 1a TRG‐LN. Less than one‐third of all ESCC cells were degenerated (enclosed by the dotted lines), and residual ESCC cells within the area enclosed by solid lines are observed. C, Residual ESCC cells are observed accompanied by degenerated ESCC cells within the area enclosed by black arrowheads. The micrograph is an enlarged image of the squared area of (B). D, Grade 1b TRG‐LN. More than one‐third and less than two‐thirds of all ESCC cells were degenerated and tissue modification is observed (enclosed by the dotted line), replacing the space where necrotic ESCC cells existed before neoadjuvant therapy, and residual ESCC cells within the area enclosed by solid lines are observed. E, Grade 2 TRG‐LN. More than two‐thirds of all ESCC cells were degenerated (enclosed by the dotted line) and a few residual ESCC cells within the area enclosed by the solid line are observed. F, Small numbers of degenerated ESCC cells within the area enclosed by black arrowheads are observed accompanied by necrotic keratinizing materials originating from ESCC cells. The micrograph is an enlarged image of the squared area of (E). G, Grade 3 TRG‐LN. No viable ESCC cells are observed although tissue modification is observed (enclosed by the dotted line). H, Tissue modification such as granulomatous reaction is shown. Only keratinizing materials accompanied by infiltration of foreign body types and multinucleated macrophages are observed. The micrograph is an enlarged image of the squared area of (G)](CAS-109-2046-g001){#cas13596-fig-0001}

2.5. Statistical analysis {#cas13596-sec-0007}
-------------------------

Recurrence‐free survival curves were estimated using the Kaplan‐Meier method and were compared using the log‐rank test. RFS was defined as the period from the date of surgery until the date of death or recurrence which was clinically confirmed through endoscopy or CECT. OS period was defined as the time from the date of surgery until the last confirmed date of survival or death, regardless of the cause of death. Univariate Cox proportional hazards model was used to examine the association between all clinicopathological factors including CER and death or recurrence. Variables with a *P*‐value \<.10 were evaluated simultaneously using a multivariate analysis with the Cox proportional hazards model. We conducted multivariate analyses including at least 8 outcome variables according to standard statistical methods. Next, clinicopathological factors were used to examine the difference between 2 subgroups (grade 0 TRG‐PT vs grade 1a‐3 TRG‐PT), using univariate and multivariate analyses. All statistical analyses were done using the IBM SPSS statistical software package (version 22.0 for Mac; IBM Japan Ltd, Tokyo, Japan). All *P*‐values were reported as 2‐sided, with a significance level of .05.

3. RESULTS {#cas13596-sec-0008}
==========

3.1. Patients and clinicopathological characteristics {#cas13596-sec-0009}
-----------------------------------------------------

Clinical characteristics of the 110 patients who were enrolled in this study are shown in Table [1](#cas13596-tbl-0001){ref-type="table-wrap"}. Male patients were predominant (82.7%), and the median age was 66 years (range, 42‐77). Ten patients (9.1%) were diagnosed with non‐regional lymph node metastasis clinically and regarded as cStage IV. Seventy patients (63.6%) underwent nCT with the CF regimen, and the remaining 40 patients (36.4%) underwent nCT with the DCF regimen prior to surgery. Of these, 44 (62.9%) and 23 (57.5%) patients underwent a full course of each regimen, respectively.

###### 

Clinical and pathological characteristics of patients in the present study

                                          N (%)
  --------------------------------------- ------------
  Gender                                  
  Male                                    91 (82.7)
  Female                                  19 (17.3)
  Age (y)                                 
  Median (range)                          66 (42‐77)
  Tumor location                          
  Upper thoracic                          14 (12.7)
  Middle thoracic                         59 (53.6)
  Lower thoracic                          34 (30.9)
  Abdominal                               3 (2.7)
  cT stage                                
  1                                       8 (7.3)
  2                                       14 (12.7)
  3                                       88 (80.0)
  cN stage                                
  0                                       24 (21.8)
  1                                       53 (48.1)
  2                                       30 (27.3)
  3                                       3 (2.7)
  cM stage                                
  0                                       100 (90.9)
  1                                       10 (9.1)
  cStage                                  
  IB                                      6 (5.5)
  IIA                                     17 (15.5)
  IIB                                     11 (10.0)
  IIIA                                    43 (39.1)
  IIIB                                    21 (19.1)
  IIIC                                    2 (1.8)
  IV                                      10 (9.1)
  Chemotherapy regimen                    
  CF                                      70 (63.6)
  DCF                                     40 (36.4)
  Planned chemotherapy course completed   
  Yes                                     67 (60.9)
  CF: 2 courses                           44 (62.9)
  DCF: 3 courses                          23 (57.5)
  No                                      43 (39.1)
  ypT stage                               
  0                                       6 (5.5)
  1                                       27 (24.5)
  2                                       13 (11.8)
  3                                       60 (54.5)
  4                                       4 (3.6)
  ypN stage                               
  0                                       17 (15.5)
  1                                       50 (45.5)
  2                                       30 (27.3)
  3                                       13 (11.8)
  ypM stage                               
  0                                       101 (91.8)
  1                                       9 (8.2)
  ypStage                                 
  0                                       5 (4.5)
  IA                                      5 (4.5)
  IB                                      3 (2.7)
  IIA                                     5 (4.5)
  IIB                                     20 (18.2)
  IIIA                                    33 (30.0)
  IIIB                                    18 (16.4)
  IIIC                                    12 (10.9)
  IV                                      9 (8.2)
  Histological differentiation            
  Well differentiated                     18 (16.4)
  Moderately differentiated               68 (61.8)
  Poorly differentiated                   24 (21.8)
  TRG‐PT                                  
  Grade 0                                 43 (39.1)
  Grade 1a                                41 (37.2)
  Grade 1b                                13 (11.8)
  Grade 2                                 8 (7.3)
  Grade 3                                 5 (4.5)
  Lymphatic infiltration                  
  0                                       62 (56.4)
  1                                       33 (30.0)
  2                                       9 (8.2)
  3                                       6 (5.5)
  Venous infiltration                     
  0                                       47 (42.7)
  1                                       45 (40.9)
  2                                       16 (14.5)
  3                                       2 (1.8)
  Residual tumor                          
  R0 (complete resection)                 102 (92.7)
  R1 (incomplete resection)               8 (7.3)
  CER                                     
  LCER                                    47 (42.7)
  HCER                                    63 (57.3)

CER, chemotherapy‐effective rate; CF, cisplatin + 5‐FU; DCF, docetaxel + cisplatin + 5‐fluorouracil; HCER, high chemotherapy‐effective rate; LCER, low chemotherapy‐effective rate; TRG‐PT, tumor regression grade of primary tumor.

John Wiley & Sons, Ltd

3.2. TRG‐PT, TRG‐LN, and CER {#cas13596-sec-0010}
----------------------------

Number of patients with grades 0, 1a, 1b, 2, and 3 TRG‐PT were 43, 41, 13, 8, and 5, respectively. Number of patients with LCER and HCER were 47 (42.7%) and 63 (57.3%), respectively. Ratios of HCER in patients with grades 0, 1a, 1b, 2, and 3 TRG‐PT were 39.5% (17/43), 58.5% (24/41), 84.6% (11/13), 75.0% (6/8), and 100.0% (5/5), respectively (Table [S1](#cas13596-sup-0005){ref-type="supplementary-material"}).

3.3. Recurrence‐free survival and overall survival analysis {#cas13596-sec-0011}
-----------------------------------------------------------

Median follow up was 25.5 months (range, 1.8‐77.2 months). In the follow‐up period, recurrence rate was 48.2% (53 of 110) and death occurred in 41 patients (37.3%). Kaplan‐Meier curves for RFS according to TRG‐PT are shown in Figure [2](#cas13596-fig-0002){ref-type="fig"}A,B. Patients with grades 1a‐3 TRG‐PT had significantly longer RFS rates than patients with grade 0 (*P *= .003). In addition, patients with LCER had significantly shorter RFS and OS rates than patients with HCER (*P *= .0014 and .0012), as shown in Figure [2](#cas13596-fig-0002){ref-type="fig"}C,D. In the analyses using the highest and the lowest TRG‐LN grade, there were no clear correlations between RFS, and the highest TRG‐LN grade or the lowest TRG‐LN grade unless the lowest TRG‐LN grade was 0 or 3 (Figure [S2](#cas13596-sup-0002){ref-type="supplementary-material"}A,B), suggesting that overall evaluation of all pp‐MLN in each patient may successfully predict prognosis rather than individual evaluation of pp‐MLN such as the highest TRG‐LN or the lowest TRG‐LN regarding pp‐MLN.

![Recurrence‐free survival (RFS) and overall survival (OS) curves according to tumor regression grade of primary tumor (TRG‐PT) or chemotherapy‐effective rate (CER). A, RFS curves according to TRG‐PT including grades 0, 1a, 1b, 2, and 3. B, RFS curves of the 2 groups of grade 0 TRG‐PT and grades 1a, 1b, 2, and 3. There was a significant difference between the grade 0 group and the grades 1a, 1b, 2, and 3 group (*P *= .003). C, RFS curves of low CER (LCER) and high CER (HCER). There was a significant difference in RFS between LCER and HCER groups (*P *= .0014). D, OS curves of LCER and HCER. There was a significant difference in OS between LCER and HCER groups (*P *= .0012)](CAS-109-2046-g002){#cas13596-fig-0002}

3.4. Prognostic factors in univariate and multivariate analysis {#cas13596-sec-0012}
---------------------------------------------------------------

Univariate analysis indicated that ypT3‐4 (vs ypT0‐2, HR; 4.553, *P *\< .001), positive venous infiltration (vs negative, HR; 7.222, *P *\< .001), grade 0 TRG‐PT (vs grades 1a, 1b, 2, and 3 TRG‐PT, HR; 2.228, *P* = .004), and LCER (vs HCER, HR; 2.367, *P* = .002) were poor prognostic factors for RFS (Table [2](#cas13596-tbl-0002){ref-type="table-wrap"}). Consequently, of the variables with a *P*‐value \<.10, 6 factors (ypT stage, ypN stage, lymphatic infiltration, venous infiltration, TRG‐PT, and CER) were selected for multivariable analyses. This showed that ypT3‐4 (vs ypT0‐2, HR; 2.551, *P* = .023), positive venous infiltration (vs negative, HR; 3.526, *P* = .006), and LCER (vs HCER, HR; 1.922, *P* = .033) were predictors of shorter RFS.

###### 

Univariate and multivariate logistic regression model of the pathological predictors of RFS

                                          N (%)   Univariate analysis   Multivariate analysis                                                 
  --------------------------------------- ------- --------------------- ----------------------- -------------- -------- ------- ------------- ------
  Age (y)                                                                                                                                     
  \<65                                    59      (53.6)                Ref                                    Ref                            
  ≥65                                     51      (46.4)                0.98                    0.571‐1.684    .943                           
  Gender                                                                                                                                      
  Male                                    91      (82.7)                Ref                                    Ref                            
  Female                                  19      (17.3)                1.022                   0.499‐2.094    .953                           
  Chemotherapy regimen                                                                                                                        
  CF                                      70      (63.6)                Ref                                    Ref                            
  DCF                                     40      (36.4)                0.663                   0.364‐1.205    .177                           
  Planned chemotherapy course completed                                                                                                       
  Yes                                     67      (60.9)                Ref                                    Ref                            
  No                                      43      (39.1)                0.926                   0.533‐1.606    .783                           
  ypT stage                                                                                                                                   
  0‐2                                     22      (20.0)                Ref                                    Ref      Ref                   Ref
  3‐4                                     88      (80.0)                4.553                   2.281‐9.089    \<.001   2.551   1.135‐5.730   .023
  ypN stage                                                                                                                                   
  0                                       17      (15.5)                Ref                                    Ref      Ref                   Ref
  1‐3                                     93      (84.5)                2.736                   0.986‐7.590    .053     0.961   0.311‐2.969   .945
  ypM stage                                                                                                                                   
  0                                       101     (91.8)                Ref                                    Ref                            
  1                                       9       (8.2)                 2.242                   0.957‐5.253    .063                           
  Residual tumor                                                                                                                              
  Residual tumor                                                                                               Ref                            
  R1 (incomplete resection)               8       (7.3)                 2.337                   0.928‐5.888    .072                           
  Histological differentiation                                                                                                                
  Well, Moderately differentiated         86      (78.2)                Ref                                    Ref                            
  Poorly differentiated                   24      (21.8)                0.55                    0.259‐1.167    .12                            
  Lymphatic infiltration                                                                                                                      
  Negative                                62      (56.4)                Ref                                    Ref      Ref                   Ref
  Positive                                48      (44.6)                1.618                   0.943‐2.776    .081     0.966   0.551‐1.693   .904
  Venous infiltration                                                                                                                         
  Negative                                47      (42.7)                Ref                                    Ref      Ref                   Ref
  Positive                                63      (57.3)                7.222                   3.382‐15.422   \<.001   3.526   1.429‐8.704   .006
  TRG‐PT                                                                                                                                      
  Grade 0                                 43      (39.1)                2.228                   1.295‐3.832    .004     1.531   0.847‐2.767   .159
  Grade 1a, 1b, 2, and 3                  67      (60.9)                Ref                                    Ref      Ref                   Ref
  CER                                                                                                                                         
  LCER                                    47      (42.7)                2.367                   1.371‐4.085    .002     1.922   1.056‐3.500   .033
  HCER                                    63      (57.3)                Ref                                    Ref      Ref                   Ref

CER, chemotherapy‐effective rate; CF, cisplatin + 5‐FU; DCF, docetaxel + cisplatin + 5‐fluorouracil; HCER, high chemotherapy‐effective rate; LCER, low chemotherapy‐effective rate; RFS, recurrence‐free survival; TRG‐PT, tumor regression grade of primary tumor.

John Wiley & Sons, Ltd

3.5. Significance of combining TRG‐PT and CER for prognostic factors {#cas13596-sec-0013}
--------------------------------------------------------------------

Next, we investigated whether a combination of CER and TRG‐PT would allow classification of subgroups associated with patient prognosis. As an interaction between TRG‐PT and CER in RFS in the Cox model was observed (*P* = .132), we examined whether CER was a prognostic factor in each subgroup (TRG‐PT grade 0 group, and grades 1a, 1b, 2, and 3 group). RFS curves according to CER in patients according to grade 0 and grades 1a‐3 TRG‐PT groups is shown in Figure [3](#cas13596-fig-0003){ref-type="fig"}A,B. LCER was a significant poor prognostic factor for RFS among patients with grade 0 TRG‐PT (*P* = .0028); however, LCER was not a significant poor prognostic factor for RFS among patients with grade 1a or 1b or 2 or 3 TRG‐PT (*P* = .476). For OS, LCER was also a significant poor prognostic factor among patients with grade 0 TRG‐PT (*P *=* *.015), not among patients with grades 1a‐3 TRG‐PT (*P* = .196), as shown in Figure [3](#cas13596-fig-0003){ref-type="fig"}C,D.

![Recurrence‐free survival (RFS) and overall survival (OS) curves of low chemotherapy‐effective rate (LCER) and high chemotherapy‐effective rate (HCER) groups in the grade 0 tumor regression grade of primary tumor (TRG‐PT) group and in the grades 1a, 1b, 2, and 3 TRG‐PT group. A, RFS curves of LCER and HCER groups in patients with grade 0 TRG‐PT. There was a significant difference between LCER and HCER groups (*P *= .0028). B, RFS curves of LCER and HCER groups in patients with grades 1a, 1b, 2, and 3 TRG‐PT. There was not a significant difference between LCER and HCER groups (*P *= .476). C, OS curves of LCER and HCER groups in patients with grade 0 TRG‐PT. There was a significant difference between the LCER and HCER groups (*P *= .015). D, OS curves of LCER and HCER groups in patients with grades 1a, 1b, 2, and 3 TRG‐PT. There was not a significant difference between the LCER and HCER groups (*P *= .196)](CAS-109-2046-g003){#cas13596-fig-0003}

For patients with grade 0 TRG‐PT, univariate analyses showed that the ypT factor (ypT3‐4), venous infiltration, and LCER were predictors of a shorter RFS (Table [3](#cas13596-tbl-0003){ref-type="table-wrap"}). Multivariate analysis showed that ypT3‐4 (vs ypT0‐2, HR; 3.397, *P* = .033) and LCER (vs HCER, HR; 3.543, *P* = .008) were predictors of a shorter RFS. Patients with grade 0 TRG‐PT and LCER had shorter RFS rates, and there was little difference between RFS rates of patients with grade 0 TRG‐PT and HCER, and patients with grades 1a‐3, regardless of the CER (Figure [S3](#cas13596-sup-0003){ref-type="supplementary-material"}).

###### 

Univariate and multivariate logistic regression model of the pathological predictors of RFS for patients with grade 0 TRG‐PT

                                          N (%)   Univariate analysis   Multivariate analysis                                                 
  --------------------------------------- ------- --------------------- ----------------------- --------------- ------ ------- -------------- ------
  Age (y)                                                                                                                                     
  \<65                                    22      (51.2)                Ref                                     Ref                           
  ≥65                                     21      (48.8)                0.956                   0.455‐2.008     .906                          
  Gender                                                                                                                                      
  Male                                    37      (86.0)                Ref                                     Ref                           
  Female                                  6       (14.0)                2.135                   0.850‐5.361     .106                          
  Chemotherapy regimen                                                                                                                        
  CF                                      37      (86.0)                Ref                                     Ref                           
  DCF                                     6       (14.0)                1.271                   0.438‐3.69      .659                          
  Planned chemotherapy course completed                                                                                                       
  Yes                                     24      (55.8)                Ref                                     Ref                           
  No                                      19      (44.2)                0.708                   0.331‐1.515     .374                          
  ypT stage                                                                                                                                   
  0‐2                                     16      (37.2)                Ref                                     Ref    Ref                    Ref
  3‐4                                     27      (62.8)                4.823                   1.812‐12.838    .002   3.397   1.104‐10.453   .033
  ypN stage                                                                                                                                   
  0                                       1       (2.3)                 Ref                                     Ref                           
  1‐3                                     42      (97.7)                21.463                  0.004‐118 603   .486                          
  ypM stage                                                                                                                                   
  0                                       40      (93.0)                Ref                                     Ref                           
  1                                       3       (7.0)                 0.415                   0.056‐3.068     .389                          
  Residual tumor                                                                                                                              
  R0 (complete resection)                 38      (88.4)                Ref                                     Ref                           
  R1 (incomplete resection)               5       (11.6)                0.994                   0.299‐3.302     .992                          
  Histological differentiation                                                                                                                
  Well, Moderately differentiated         35      (81.4)                Ref                                     Ref                           
  Poorly differentiated                   8       (18.6)                0.643                   0.223‐1.857     .415                          
  Lymphatic infiltration                                                                                                                      
  Negative                                19      (44.2)                Ref                                     Ref                           
  Positive                                24      (55.8)                1.287                   0.603‐2.751     .514                          
  Venous infiltration                                                                                                                         
  Negative                                10      (23.2)                Ref                                     Ref    Ref                    Ref
  Positive                                33      (76.8)                8.432                   1.973‐36.036    .004   3.098   0.585‐16.406   .184
  CER                                                                                                                                         
  LCER                                    26      (60.4)                3.534                   1.473‐8.479     .005   3.543   1.401‐8.963    .008
  HCER                                    17      (39.6)                Ref                                     Ref    Ref                    Ref

CER, chemotherapy‐effective rate; CF, cisplatin + 5‐FU; DCF, docetaxel + cisplatin + 5‐fluorouracil; HCER, high chemotherapy‐effective rate; LCER, low chemotherapy‐effective rate; RFS, recurrence‐free survival; TRG‐PT, tumor regression grade of primary tumor.

John Wiley & Sons, Ltd

3.6. Relationship between RFS, and TRG‐PT or CER in patients with ypStage II or III {#cas13596-sec-0014}
-----------------------------------------------------------------------------------

In cases of dividing the patients with ypStage III into 2 groups, including the patients with grade 0 TRG‐PT and the patients with grades 1a‐3 TRG‐PT, the latter patients were shown to have significantly longer RFS compared with those of the former patients (*P* = .0015), implying that TRG‐PT may have an impact on RFS (Figure [S4](#cas13596-sup-0004){ref-type="supplementary-material"}A). In contrast, the same analysis in patients with ypStage II did not show any significant difference between the patients with grades 1a‐3 TRG‐PT and those with grade 0 TRG‐PT (*P* = .91) (Figure [S4](#cas13596-sup-0004){ref-type="supplementary-material"}A). This might be attributed to the small sample size of the patients with ypStage II (n = 25).

In cases of dividing the patients with ypStage III into 2 groups, including the patients with HCER and the patients with LCER, the former patients were shown to have significantly longer RFS compared with those of the latter patients (*P* = .020), implying that CER may have an impact on RFS (Figure [S4](#cas13596-sup-0004){ref-type="supplementary-material"}B). In contrast, the same analysis in patients with ypStage II did not show any significant difference between the patients with HCER and those with LCER (*P *= 0.17) (Figure [S4](#cas13596-sup-0004){ref-type="supplementary-material"}B). This might be attributed to the small sample size of the patients with ypStage II (n = 25). However, the number of patients with ypStage I or IV was so small that it was impossible to conduct the same statistical analyses as described above (Table [S2](#cas13596-sup-0006){ref-type="supplementary-material"}).

4. DISCUSSION {#cas13596-sec-0015}
=============

Lymph node metastasis is a critical negative prognostic factor in ESCC patients. Some previous investigators attempted to classify ESCC patients who received neoadjuvant therapy including nCT and nCRT followed by surgery, according to a combination of TRG‐PT and residual LNM; however, these classifiers could not be used to divide patients with completely different prognoses.[11](#cas13596-bib-0011){ref-type="ref"}, [12](#cas13596-bib-0012){ref-type="ref"}, [13](#cas13596-bib-0013){ref-type="ref"}, [14](#cas13596-bib-0014){ref-type="ref"}, [15](#cas13596-bib-0015){ref-type="ref"}, [16](#cas13596-bib-0016){ref-type="ref"} It is possible that TRG‐PT reflects the neoadjuvant therapeutic effect on the primary tumor, whereas ypN stage reflects only the residual tumor in LN after neoadjuvant therapy. In other words, ypN stage cannot reflect the degree of the therapeutic effect on tumor cells in metastatic LN, according to nCT. This suggests that it might be necessary to evaluate the degree of tumor regression in metastatic LN; therefore, we created a new category, CER, which could reflect the degree of the neoadjuvant therapeutic effect. In the present study, CER was shown to be an independent predictor for a poor prognosis, especially in patients with grade 0 TRG‐PT. This suggested that the chemotherapeutic effect in LN might be a better prognostic factor, even with residual tumor at the primary site as well as in breast cancer.[7](#cas13596-bib-0007){ref-type="ref"}

In the present study, CER could be used to identify the patient group with the worst prognosis that was not selected by only TRG‐PT as one of the classifiers. That is, patients with grade 0 TRG‐PT and residual LNM with an LCER had a worse prognosis. Currently, nCT or nCRT followed by surgery is one of the standard treatments in Japan based on results from some clinical trials comparing the therapeutic effect of only surgery with that of surgery followed by adjuvant CT or CRT. However, trial results showed that the 5‐year overall survival and progression‐free survival was not so high (55% and 44%).[3](#cas13596-bib-0003){ref-type="ref"} Therefore, a new therapeutic strategy needs to be established for patients who do not respond to neoadjuvant therapy. As a first step, candidate patients requiring a new therapeutic strategy should be narrowed down by using our new categories, for example, CER.

In the present study, we examined all LN dissected together with the primary resected tumor, according to the same classification as that of TRG‐PT, and could set the CER for LN as an independent prognostic factor. Because our study was retrospective in nature, and enrolled patients from one institution only, it will be necessary to carry out a validation study in another cohort.

In conclusion, our study showed that accurate evaluation of TRG‐LN under the microscope, in addition to TRG‐PT, allowed us to predict the prognosis of patients who had received nCT followed by surgery.
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